drugset / Trial / NCT02305849

A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment

NCT02305849

Phase 3 Completed 519 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study was to verify the efficacy of ASP015K versus placebo administrated in combination with methotrexate (MTX) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response to MTX

Timeline

Start
2014-07-25
Primary completion
2017-06-20
Completion
2017-11-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject peficitinib Small molecule 100 mg Oral
Subject peficitinib Small molecule 150 mg Oral
Background Methotrexate Small molecule

Indications